Knights of Columbus Asset Advisors LLC Has $1.64 Million Position in PTC Therapeutics, Inc. (NASDAQ:PTCT)

Knights of Columbus Asset Advisors LLC increased its position in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 104.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 59,424 shares of the biopharmaceutical company's stock after acquiring an additional 30,309 shares during the quarter. Knights of Columbus Asset Advisors LLC owned 0.08% of PTC Therapeutics worth $1,638,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. grew its position in PTC Therapeutics by 99.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,941 shares of the biopharmaceutical company's stock valued at $43,000 after purchasing an additional 969 shares in the last quarter. Nisa Investment Advisors LLC grew its position in PTC Therapeutics by 317.0% in the third quarter. Nisa Investment Advisors LLC now owns 2,656 shares of the biopharmaceutical company's stock worth $60,000 after acquiring an additional 2,019 shares in the last quarter. Lazard Asset Management LLC grew its position in PTC Therapeutics by 115.1% in the fourth quarter. Lazard Asset Management LLC now owns 2,478 shares of the biopharmaceutical company's stock worth $94,000 after acquiring an additional 1,326 shares in the last quarter. Allspring Global Investments Holdings LLC grew its position in PTC Therapeutics by 12.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 5,075 shares of the biopharmaceutical company's stock worth $114,000 after acquiring an additional 559 shares in the last quarter. Finally, Point72 Hong Kong Ltd bought a new stake in PTC Therapeutics in the second quarter worth approximately $161,000.

Insider Transactions at PTC Therapeutics

In related news, Director Allan Steven Jacobson sold 10,000 shares of the company's stock in a transaction dated Monday, January 22nd. The shares were sold at an average price of $27.38, for a total value of $273,800.00. Following the sale, the director now owns 12,348 shares of the company's stock, valued at $338,088.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last three months, insiders sold 13,043 shares of company stock valued at $355,650. Company insiders own 5.30% of the company's stock.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. TD Cowen decreased their target price on shares of PTC Therapeutics from $32.00 to $30.00 and set a "market perform" rating for the company in a research report on Friday, March 1st. Royal Bank of Canada boosted their target price on shares of PTC Therapeutics from $22.00 to $28.00 and gave the stock a "sector perform" rating in a research report on Friday, March 1st. Jefferies Financial Group boosted their price objective on shares of PTC Therapeutics from $33.00 to $35.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. Finally, Cantor Fitzgerald restated an "overweight" rating and issued a $45.00 price objective on shares of PTC Therapeutics in a research note on Friday, April 12th. Five research analysts have rated the stock with a sell rating, six have given a hold rating and three have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus price target of $33.53.

PTC Therapeutics Trading Up 2.6 %

NASDAQ:PTCT traded up $0.63 during trading hours on Friday, hitting $25.32. 3,931,888 shares of the company traded hands, compared to its average volume of 607,996. The stock has a market capitalization of $1.94 billion, a price-to-earnings ratio of -3.03 and a beta of 0.67. PTC Therapeutics, Inc. has a twelve month low of $17.53 and a twelve month high of $59.84. The firm has a 50-day moving average of $28.08 and a 200 day moving average of $25.69.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last released its earnings results on Thursday, February 29th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $0.29 by ($0.53). The company had revenue of $307.06 million for the quarter, compared to analysts' expectations of $315.90 million. Equities research analysts predict that PTC Therapeutics, Inc. will post -5.94 earnings per share for the current fiscal year.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.